Modeling and simulation of count data

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 8, 2014, Pages

  Plan, E L ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Department of Clinical Pharmacology and Pharmacometrics and Pharmetheus AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906853438     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.27     Document Type: Article

References (63)

1. Barrett, J.S., Fossler, M.J., Cadieu, K.D. & Gastonguay, M.R. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J. Clin. Pharmacol. 48, 632-649 (2008).
2. Rowland, M., Benet, L.Z. & Riegelman, S. Two-compartment model for a drug and its metabolite: application to acetylsalicylic acid pharmacokinetics. J. Pharm. Sci. 59, 364-367 (1970).
3. Sheiner, L.B. & Beal, S.L. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm. 8, 553-571 (1980).
4. Paule, I., Girard, P., Freyer, G. & Tod, M. Pharmacodynamic models for discrete data. Clin. Pharmacokinet. 51, 767-786 (2012).
5. Mould, D.R. & Upton, R.N. Basic concepts in population modeling, simulation, and modelbased drug development. CPT Pharmacometrics Syst. Pharmacol. 1, e6 (2012).
6. Holford, N. A time to event tutorial for pharmacometricians. CPT: Pharmacometrics Syst. Pharmacol. 2, e43 (2013).
7. Frame, B., Miller, R. & Lalonde, R.L. Evaluation of mixture modeling with count data using NONMEM. J. Pharmacokinet. Pharmacodynamics 30, 167-183 (2003).
8. Gupta, S.K., Sathyan, G., Lindemulder, E.A., Ho, P.L., Sheiner, L.B. & Aarons, L. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin. Pharmacol. Ther. 65, 672-684 (1999).
9. Wirz, S., Wartenberg, H.C. & Nadstawek, J. Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. Support. Care Cancer 16, 999-1009 (2008).
10. Sheiner, L.B. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metabolism Rev. 15, 153-171 (1984).
11. Plan, E.L., Ma, G., Någård, M., Jensen, J. & Karlsson, M.O. Transient lower esophageal sphincter relaxation pharmacokinetic- pharmacodynamic modeling: count model and repeated time-to-event model. J. Pharmacol. Experiment. Ther. 339, 878-885 (2011).
12. Siméon Denis Poisson and Christian Heinrich Schnuse. Recherches sur la Probabilité des Jugements en matière criminelle et en matière civile. (Meyer, Parris, France, 1841).
13. de Moivre, A. De mensura sorits seu, de probabilitate eventuum in ludis a casu fortuito pendentibus. (1711).
14. Holford, T.R. The analysis of rates and of survivorship using log-linear models. Biometrics 36, 299-305 (1980).
15. Laird, N. & Olivier, D. Covariance analysis of censored survival data using log-linear analysis techniques. J. Am. Stat. Association 76, 231-240 (1981).
16. Upton, R.N. & Mould, D.R. Basic concepts in population modeling, simulation, and modelbased drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst. Pharmacol. 3, e88 (2014).
17. Mould, D.R. & Upton, R.N. Basic concepts in population modeling, simulation, and modelbased drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst. Pharmacol. 2, e38 (2013).
18. Hoel, P.G. On indices of dispersion. Ann. Math. Stat. 14, 155-162 (1943).
19. Selby, B. The index of dispersion as a test statistic. Biometrika 52, 627-629 (1965).
20. Hoaglin, D.C. A Poissonness plot. The American Statistician 34, 146-149 (1980).
21. Hoaglin, D.C., Mosteller, F. & Tukey, J.W. Exploring Data Tables, Trends, and Shapes. (John Wiley & Sons, Hoboken, NJ, 2011).
22. Gardner, W., Mulvey, E.P. & Shaw, E.C. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol. Bull. 118, 392-404 (1995).
23. Land, K.C., McCall, P.L. & Nagin, D.S. A comparison of Poisson, negative binomial, and semiparametric mixed Poisson regression models with empirical applications to criminal careers data. Sociological Methods & Research 24, 387-442 (1996).
24. Trocóniz, I.F., Plan, E.L., Miller, R. & Karlsson, M.O. Modelling overdispersion and Markovian features in count data. J. Pharmacokinet. Pharmacodyn. 36, 461-477 (2009).
25. Ahn, J.E., Plan, E.L., Karlsson, M.O. & Miller, R. Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment. J. Clin. Pharmacol. 52, 880-892 (2012).
26. Lloyd-Smith, J.O., Schreiber, S.J., Kopp, P.E. & Getz, W.M. Superspreading and the effect of individual variation on disease emergence. Nature 438, 355-359 (2005).
27. Consul, P.C. & Jain, G.C. A generalization of the Poisson distribution. Technometrics 15, 791 (1973).
28. Consul, P.C. & Shoukri, M.M. The generalized poisson distribution when the sample mean is larger than the sample variance. Communications in Statistics - Simulation and Computation 14, 667-681 (1985).
29. Efron, B. Double exponential families and their use in generalized linear regression. J. Am. Stat. Association 81, 709 (1986).
30. Ridout, M.S. & Besbeas, P. An empirical model for underdispersed count data. Statistical Modelling 4, 77-89 (2004).
31. Bonate, P.L., Sung, C., Welch, K. & Richards, S. Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme. J. Pharmacokinet Pharmacodyn. 36, 443-459 (2009).
32. Ambagaspitiya, R.S. & Balakrishnan, N. On the compound generalized Poisson distributions. Astin Bulletin 24, 255-263 (1994).
33. King, G. Variance specification in event count models: from restrictive assumptions to a generalized estimator. Am. J. Political Sci. 33, 762-784 (1989).
34. Winkelmann, R. & Zimmermann, K.F. Count data models for demographic data. Math. Popul. Stud. 4, 205-221, 223 (1994).
35. Zou, Y., Lord, D. & Geedipally, S.R. Over- and Under-Dispersed Count Data: Comparing Conway-Maxwell-Poisson and Double-Poisson Distributions. Transportation Research Board 91st Annual Meeting, Washington, DC, USA, 2012.
36. Zou, Y., Geedipally, S.R. & Lord, D. Evaluating the Double Poisson Generalized Linear Model. Transportation Research Board 92nd Annual Meeting, Washington, DC, USA, 2013.
37. Plan, E.L., Elshoff, J.P., Stockis, A., Sargentini-Maier, M.L. & Karlsson, M.O. Likert pain score modeling: a Markov integer model and an autoregressive continuous model. Clin. Pharmacol. Ther. 91, 820-828 (2012).
38. Karlsson, M.O., Beal, S.L. & Sheiner, L.B. Three new residual error models for population PK/PD analyses. J. Pharmacokinet. Biopharmaceutics 23, 651-672 (1995).
39. Tornøe, C.W., Overgaard, R.V., Agersø, H., Nielsen, H.A., Madsen, H. & Jonsson, E.N. Stochastic differential equations in NONMEM®: implementation, application, and comparison with ordinary differential equations. Pharmaceutical Res. 22, 1247-1258 (2005).
40. Baum, L.E. & Petrie, T. Statistical inference for probabilistic functions of finite state Markov chains. Ann. Math. Stat. 37, 1554-1563 (1966).
41. Delattre, M., Savic, R.M., Miller, R., Karlsson, M.O. & Lavielle, M. Analysis of exposure- response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology. J. Pharmacokinet. Pharmacodyn. 39, 263-271 (2012).
42. Zeger, S.L. & Qaqish, B. Markov regression models for time series: a quasi-likelihood approach. Biometrics 44, 1019 (1988).
43. Velez de Mendizabal, N., Trocóniz, I.F., Hutmacher, M.M. & Bies, R. Discrete distribution models for relapsing-remitting dynamics observed in multiple sclerosis. PAGE 21 (2012).
44. Schoemaker, R., Snoeck, E. & Stockis, A. Exposure-response modeling of daily seizure counts in focal epilepsy trials. PAGE 19 (2010).
45. Singpurwalla, N.D. The hazard potential. J. Am. Stat. Association 101, 1705-1717 (2006).
46. Cox, E.H., Veyrat-Follet, C., Beal, S.L., Fuseau, E., Kenkare, S. & Sheiner, L.B. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron. J. Pharmacokinet. Biopharmaceutics 27, 625-644 (1999).
47. Simeoni, M. et al. Counting events: population approaches using NONMEM. PAGE 14, 2005.
48. Plan, E.L., Karlsson, K.E. & Karlsson, M.O. Approaches to simultaneous analysis of frequency and severity of symptoms. Clin. Pharmacol. Ther. 88, 255-259 (2010).
49. Yano, I., Beal, S.L. & Sheiner, L.B. The need for mixed-effects modeling with population dichotomous data. J. Pharmacokinet. Pharmacodyn. 28, 389-412 (2001).
50. Plan, E.L., Maloney, A., Trocóniz, I.F. & Karlsson, M.O. Performance in population models for count data, part I: maximum likelihood approximations. J. Pharmacokinet. Pharmacodyn. 36, 353-366 (2009).
51. Savic, R. & Lavielle, M. Performance in population models for count data, part II: A new SAEM algorithm. J. Pharmacokinet. Pharmacodyn. 36, 367-379 (2009).
52. Metrum Institute. MI255: Exposure-Response Modeling of Categorical, Count, and Timeto-Event Data Using Bayesian Methods. 〈http://www.youtube. com/metruminst〉. (2011). Lecture 6.
53. Pierce, D.A. & Schafer, D.W. Residuals in generalized linear models. J. Am. Statistical Association 81, 977-986 (1986).
54. Lindbom, L., Pihlgren, P., Jonsson, E.N. & Jonsson, N. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Computer Methods and Programs in Biomedicine 79, 241-257 (2005).
55. Keizer, R.J., Karlsson, M.O. & Hooker, A. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst. Pharmacol. 2, e50 (2013).
56. Jonker, D.M., van de Mheen, C., Eilers, P.H., Kruk, M.R., Voskuyl, R.A. & Danhof, M. Anticonvulsant drugs differentially suppress individual ictal signs: a pharmacokinetic/ pharmacodynamic analysis in the cortical stimulation model in the rat. Behav. Neurosci. 117, 1076-1085 (2003).
57. Ito, K. & Murphy, D. Application of ggplot2 to Pharmacometric Graphics. CPT Pharmacometrics Syst. Pharmacol. 2, e79 (2013).
58. Box, J.F. R.A. Fisher and the design of experiments, 1922-1926. The American Statistician 34, 1-7 (1980).
59. Nestorov, I., Graham, G., Duffull, S., Aarons, L., Fuseau, E. & Coates, P. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm. Res. 18, 1210-1219 (2001).
60. Ogungbenro, K. & Aarons, L. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations. J. Biopharmaceutical Stat. 18, 1212-1227 (2008).
61. Nyberg, J., Karlsson, M.O. & Hooker, A. Population optimal experimental design for discrete type data. PAGE 18 (2009).
62. Cameron, A.C. & Trivedi, P.K. Regression Analysis of Count Data. (Cambridge University Press, Cambridge, England, 1998).
63. Coxe, S., West, S.G. & Aiken, L.S. The analysis of count data: a gentle introduction to poisson regression and its alternatives. J. Personality Assessment 91, 121-136 (2009).